Summary of Sadara Therapeutics Conference Call Company Overview - **Company**: Sadara Therapeutics - **Product**: CD388, a long-acting antiviral drug for the prevention of seasonal influenza Key Industry Insights - **Trial**: Phase 2b NAVIGATE trial evaluating CD388 - **Primary Endpoint**: Prevention efficacy (PE) of influenza-like illness events at 24 weeks - **Participants**: 5,041 healthy unvaccinated adults aged 18 to 64 Core Findings - **Efficacy Results**: - CD388 demonstrated statistically significant protection against symptomatic influenza: - 450 mg: 76% protection - 300 mg: 61% protection - 150 mg: 58% protection - Placebo attack rate was 2.8% [7][13] - All secondary endpoints were met with statistical significance [8][14] - **Safety Profile**: - Safety and tolerability were consistent across all dose groups with no safety signals observed [17][18] - Treatment emergent adverse events were mild to moderate, with lower incidences compared to existing antivirals [19][20] - **Statistical Significance**: - P-value for the 450 mg dose was less than 0.0001, indicating strong statistical confidence [14] Additional Insights - **Comparison to Vaccines**: - CD388's prevention efficacy exceeds the average vaccine effectiveness of approximately 40% [14] - The drug is designed to provide protection against all strains of influenza, regardless of immune status [5][6] - **Future Plans**: - Sadara plans to submit an end of Phase II meeting request to the FDA to discuss Phase III study details focusing on high-risk populations [21] - Additional results on pharmacokinetics and strain analysis are expected to be presented at scientific conferences in September 2025 [35][41] - **Commercial Considerations**: - The company is evaluating the potential transition from prefilled syringes to single-use vials for commercial presentation [29][30] - Engagement with BARDA for potential non-dilutive financing is underway [30] Conclusion - The results from the NAVIGATE trial represent a significant advancement in influenza prevention, with CD388 showing promise as a robust once-per-season treatment option for high-risk individuals. The company is poised to move forward with regulatory discussions and further development based on these encouraging findings.